NEW YORK, May 12, 2017 /PRNewswire/ --
Investments in the Healthcare sector are affected by many variables, includingpositive trends related to demographics, and negative trends related to reimbursement. The sector is made up of many different industries - from pharmaceuticals and devices, to health insurers and hospitals. Pre-market, Stock-Callers.com monitors the
On Thursday, shares in Irvine, California headquartered Endologix Inc. recorded a trading volume of 592,123 shares. The stock ended the session 3.14% lower at $7.10. The Company's shares have gained 8.90% in the last one month, 2.90% over the previous three months, and 24.13% on an YTD basis. The stock is trading 3.10% above its 50-day moving average. Moreover, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 51.59.
On May 04th, 2017, Endologix announced financial results for the three months ended March 31st, 2017. Global revenue in Q1 2017 was $42.6 million; gross profit was $28.6 million; total operating expenses were $44.3 million; and net loss was $21.3 million. In addition, total cash, cash equivalents, restricted cash, and marketable securities were $36.0 million as of March 31st, 2017. The free research report on ELGX is available at:
C. R. Bard
Murray Hill, New Jersey headquartered C. R. Bard Inc.'s stock closed the day 0.83% higher at $307.80. A total volume of 1.06 million shares was traded, which was above their three months average volume of 881,530 shares. The Company's shares have advanced 23.23% in the past month, 28.44% in the previous three months, and 37.28% since the start of this year. The stock is trading 16.61% and 31.85% above its 50-day and 200-day moving averages, respectively. Additionally, shares of C. R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 84.30.
On April 19th, 2017, C. R. Bard's Board of Directors declared a regular quarterly dividend of 26 cents per share on the Company's common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on May 12th, 2017 to shareholders of record at the close of business on May 01st, 2017.
On April 25th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Strong Buy' to 'Market Perform'. The complimentary report on BCR can be downloaded at:
Shares in Billerica, Massachusetts headquartered Insulet Corp. recorded a trading volume of 573,106 shares, which was higher than their three months average volume of 500,550 shares. The stock ended yesterday's trading session 0.03% higher at $39.11. The Company's shares have advanced 3.80% on an YTD basis. The stock is trading below its 200-day moving average by 4.00%. Furthermore, shares of Insulet, which develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally, have an RSI of 32.47.
On May 08th, 2017, Insulet announced financial results for the three months ended March 31st, 2017. Q1 2017 revenue was $101.7 million, exceeding the Company's guidance of $96 million to $99 million, and representing year-over-year growth of 25%. Gross margin was 58.4%, operating loss was $5.3 million, and net loss was $10.0 million for the quarter. Visit us today and download our complete research report on PODD for free at:
Cambridge, Massachusetts headquartered Vericel Corp.'s stock finished Thursday's session 1.92% lower at $2.55 with a total trading volume of 183,990 shares. The Company's shares are trading below their 200-day moving average by 2.04%. Shares of the Company, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have an RSI of 40.31.
On May 10th, 2017, Vericel announced that the US FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation for ixmyelocel-T - an investigational product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy. The RMAT designation is a new, expedited program established under the 21st Century Cures Act to foster the development and approval of regenerative medicine products intended for the treatment of serious diseases and conditions. Get free access to your technical report on VCEL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...
Rosacea is a chronic skin condition marked by facial redness and swelling especially around the ...
Immunotherapy is a type of treatment method that works by using certain components of a person's ...View All